185 related articles for article (PubMed ID: 26133388)
1. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
Seo GH; Cho YY; Chung JH; Kim SW
Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
[TBL] [Abstract][Full Text] [Related]
2. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
[TBL] [Abstract][Full Text] [Related]
3. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
4. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
5. Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004-2016: A Nationwide Population-Based Study.
Lee YA; Yun HR; Lee J; Moon H; Shin CH; Kim SG; Park YJ
Thyroid; 2021 Jun; 31(6):902-911. PubMed ID: 33107409
[No Abstract] [Full Text] [Related]
6. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
Ahn HY; Min HS; Yeo Y; Ma SH; Hwang Y; An JH; Choi HS; Keam B; Im SA; Park DJ; Park IA; Noh DY; Youn YK; Chung JK; Cho BY; Park SK; Park YJ
J Clin Endocrinol Metab; 2015 Sep; 100(9):3486-93. PubMed ID: 26147607
[TBL] [Abstract][Full Text] [Related]
7. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer.
Kim HO; Lee K; Lee SM; Seo GH
JAMA Intern Med; 2020 Jan; 180(1):54-61. PubMed ID: 31633736
[TBL] [Abstract][Full Text] [Related]
8. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
9. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
11. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
12. Leukemia after a small dose of radioiodine for metastatic thyroid cancer.
Bitton R; Sachmechi I; Benegalrao Y; Schneider BS
J Clin Endocrinol Metab; 1993 Nov; 77(5):1423-6. PubMed ID: 8077344
[TBL] [Abstract][Full Text] [Related]
13. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
14. Risk of thyroid cancer after exposure to 131I in childhood.
Cardis E; Kesminiene A; Ivanov V; Malakhova I; Shibata Y; Khrouch V; Drozdovitch V; Maceika E; Zvonova I; Vlassov O; Bouville A; Goulko G; Hoshi M; Abrosimov A; Anoshko J; Astakhova L; Chekin S; Demidchik E; Galanti R; Ito M; Korobova E; Lushnikov E; Maksioutov M; Masyakin V; Nerovnia A; Parshin V; Parshkov E; Piliptsevich N; Pinchera A; Polyakov S; Shabeka N; Suonio E; Tenet V; Tsyb A; Yamashita S; Williams D
J Natl Cancer Inst; 2005 May; 97(10):724-32. PubMed ID: 15900042
[TBL] [Abstract][Full Text] [Related]
15. Cancer Risk in Graves Disease with Radioactive
Kim KJ; Choi J; Kim KJ; Song E; Yu JH; Kim NH; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG
J Nucl Med; 2024 May; 65(5):693-699. PubMed ID: 38548348
[TBL] [Abstract][Full Text] [Related]
16. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
17. Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.
Boucai L; Falcone J; Ukena J; Coombs CC; Zehir A; Ptashkin R; Berger MF; Levine RL; Fagin JA
J Clin Endocrinol Metab; 2018 Nov; 103(11):4216-4223. PubMed ID: 30137527
[TBL] [Abstract][Full Text] [Related]
18. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.
Cho YY; Kim SK; Jung JH; Hahm JR; Kim TH; Chung JH; Kim SW
Endocrine; 2019 May; 64(2):293-298. PubMed ID: 30471053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
